Zymeworks (ZYME) News Today $11.44 -0.31 (-2.60%) As of 12:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Zymeworks Inc. (NYSE:ZYME) Shares Sold by BVF Inc. ILBVF Inc. IL lowered its stake in Zymeworks Inc. (NYSE:ZYME - Free Report) by 6.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 4,308,935 shares of the company's stock after selling 299,000 shares during tMay 6 at 7:30 AM | marketbeat.comZymeworks (ZYME) Projected to Post Earnings on ThursdayMay 6 at 1:17 AM | americanbankingnews.comZymeworks Inc. (NYSE:ZYME) Receives $21.00 Consensus PT from BrokeragesMay 5 at 1:35 AM | americanbankingnews.comAcuta Capital Partners LLC Acquires Shares of 67,240 Zymeworks Inc. (NYSE:ZYME)Acuta Capital Partners LLC purchased a new stake in Zymeworks Inc. (NYSE:ZYME - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The fund purchased 67,240 shares of the company's stock, valued at approximately $984,000. Zymeworks comprises 1.0% of Acuta CapitalMay 4 at 7:12 AM | marketbeat.comInvesco Ltd. Reduces Position in Zymeworks Inc. (NYSE:ZYME)Invesco Ltd. reduced its holdings in Zymeworks Inc. (NYSE:ZYME - Free Report) by 57.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 69,382 shares of the company's stock after sellinMay 4 at 3:25 AM | marketbeat.comZymeworks Inc. (NYSE:ZYME) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of Zymeworks Inc. (NYSE:ZYME - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eight ratings firms that are presently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation, five have issued a buy recommendationMay 4 at 2:43 AM | marketbeat.comQ2 Earnings Forecast for Zymeworks Issued By Leerink PartnrsZymeworks Inc. (NYSE:ZYME - Free Report) - Stock analysts at Leerink Partnrs raised their Q2 2025 EPS estimates for Zymeworks in a research report issued on Monday, April 28th. Leerink Partnrs analyst A. Berens now forecasts that the company will post earnings per share of ($0.56) for the quarterMay 3, 2025 | marketbeat.comSusquehanna Fundamental Investments LLC Purchases New Shares in Zymeworks Inc. (NYSE:ZYME)Susquehanna Fundamental Investments LLC acquired a new position in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 97,553 shares of the company's stock, valued at approximately $1,428,000. SusquehannaMay 3, 2025 | marketbeat.comZymeworks (ZYME) Expected to Announce Earnings on ThursdayZymeworks (NYSE:ZYME) will be releasing earnings after the market closes on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-zymeworks-inc-stock/)May 3, 2025 | marketbeat.comLeerink Partnrs Estimates Zymeworks' Q2 Earnings (NYSE:ZYME)May 2, 2025 | americanbankingnews.comBarclays PLC Has $3.23 Million Holdings in Zymeworks Inc. (NYSE:ZYME)Barclays PLC grew its stake in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) by 43.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 220,890 shares of the company's stock after acquiring an additional 66,506 sharesApril 30, 2025 | marketbeat.comZymeworks: A Strong Buy With Newly-Approved Cancer Drug, Excellent Financials, And Expansive PipelineApril 28, 2025 | seekingalpha.comZymeworks: Poised For Growth With Platform ValidationApril 28, 2025 | seekingalpha.comJPMorgan Chase & Co. Grows Stake in Zymeworks Inc. (NYSE:ZYME)JPMorgan Chase & Co. boosted its position in Zymeworks Inc. (NYSE:ZYME - Free Report) by 185.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 111,983 shares of the company's stock after purchasing an additional 72,703 shares during the period. JPMApril 28, 2025 | marketbeat.comZymeworks Inc.: Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual MeetingApril 26, 2025 | finanznachrichten.deZymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual MeetingApril 25, 2025 | globenewswire.comJump Financial LLC Makes New Investment in Zymeworks Inc. (NYSE:ZYME)Jump Financial LLC acquired a new position in Zymeworks Inc. (NYSE:ZYME - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 48,612 shares of the company's stock, valued at approximately $712,000. Jump FinancialApril 25, 2025 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Shares Sold by Geode Capital Management LLCGeode Capital Management LLC cut its holdings in Zymeworks Inc. (NYSE:ZYME - Free Report) by 3.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 689,884 shares of the company's stock after selling 24,031 shares during the period. Geode Capital MApril 25, 2025 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Shares Bought by Renaissance Technologies LLCRenaissance Technologies LLC lifted its position in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) by 54.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 285,700 shares of the company's stock after purchasing an additionaApril 23, 2025 | marketbeat.com33,702 Shares in Zymeworks Inc. (NYSE:ZYME) Acquired by XTX Topco LtdXTX Topco Ltd acquired a new stake in Zymeworks Inc. (NYSE:ZYME - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 33,702 shares of the company's stock, valued at approximately $493,000. SevApril 22, 2025 | marketbeat.comZymeworks Strengthens Clinical Leadership with New Senior VP AppointmentApril 21, 2025 | tipranks.comZymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical DevelopmentApril 21, 2025 | financialpost.comZymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical DevelopmentApril 21, 2025 | financialpost.comZymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical DevelopmentApril 21, 2025 | globenewswire.comZymeworks Inc. (NYSE:ZYME) Director Acquires $825,315.48 in StockZymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc bought 73,953 shares of the stock in a transaction on Wednesday, April 16th. The shares were bought at an average cost of $11.16 per share, for a total transaction of $825,315.48. Following the purchase, the director now owns 17,773,727 shares in the company, valued at $198,354,793.32. This trade represents a 0.42 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.April 20, 2025 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Buys 73,953 SharesApril 19, 2025 | insidertrades.comWalleye Capital LLC Invests $6.63 Million in Zymeworks Inc. (NYSE:ZYME)Walleye Capital LLC purchased a new position in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 452,804 shares of the company's stock, valApril 18, 2025 | marketbeat.comZymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025April 17, 2025 | financialpost.comZymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025April 17, 2025 | globenewswire.comVanguard Group Inc. Lowers Stock Holdings in Zymeworks Inc. (NYSE:ZYME)Vanguard Group Inc. lowered its position in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) by 12.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,493,288 shares of the company's stApril 15, 2025 | marketbeat.comWellington Management Group LLP Has $3.21 Million Stake in Zymeworks Inc. (NYSE:ZYME)Wellington Management Group LLP lessened its position in Zymeworks Inc. (NYSE:ZYME - Free Report) by 9.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 219,098 shares of the company's stApril 14, 2025 | marketbeat.comAmerican Century Companies Inc. Takes Position in Zymeworks Inc. (NYSE:ZYME)American Century Companies Inc. acquired a new position in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 39,942 shares of the company's stock, valued at approximately $585,000. American CentuApril 14, 2025 | marketbeat.com201,700 Shares in Zymeworks Inc. (NYSE:ZYME) Bought by Norges BankNorges Bank purchased a new stake in Zymeworks Inc. (NYSE:ZYME - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 201,700 shares of the company's stock, valued at approximately $2,953,000April 13, 2025 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Shares Sold by Massachusetts Financial Services Co. MAMassachusetts Financial Services Co. MA lessened its holdings in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) by 65.7% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 27,385 shares of the company's stock after selling 52,471 sharApril 12, 2025 | marketbeat.comTrexquant Investment LP Invests $1.49 Million in Zymeworks Inc. (NYSE:ZYME)Trexquant Investment LP purchased a new position in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 101,996 shares of the company's stock, valued at approximately $1,493,April 12, 2025 | marketbeat.comZymeworks (NYSE:ZYME) Stock Price Down 7.6% - What's Next?Zymeworks (NYSE:ZYME) Stock Price Down 7.6% - Here's What HappenedApril 9, 2025 | marketbeat.comInsider Buying: Zymeworks Inc. (NYSE:ZYME) Director Acquires 196,438 Shares of StockZymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc acquired 196,438 shares of Zymeworks stock in a transaction dated Friday, April 4th. The shares were purchased at an average price of $11.17 per share, for a total transaction of $2,194,212.46. Following the completion of the transaction, the director now directly owns 17,699,774 shares in the company, valued at approximately $197,706,475.58. The trade was a 1.12 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.April 9, 2025 | marketbeat.comZymeworks Inc. (ZYME): Among Stocks Insiders Bought in April After Trump’s Tariff RolloutApril 9, 2025 | insidermonkey.comEcor1 Capital, Llc Buys 196,438 Shares of Zymeworks Inc. (NYSE:ZYME) StockApril 8, 2025 | insidertrades.comZymeworks Inc. (NYSE:ZYME) Receives Average Recommendation of "Moderate Buy" from AnalystsZymeworks Inc. (NYSE:ZYME - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eight research firms that are covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation, five have given a buy recommendationApril 8, 2025 | marketbeat.comSchroder Investment Management Group Makes New $4.89 Million Investment in Zymeworks Inc. (NYSE:ZYME)Schroder Investment Management Group acquired a new stake in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 337,161 shares of the company's stock, valuApril 7, 2025 | marketbeat.comRaymond James Financial Inc. Purchases Shares of 60,642 Zymeworks Inc. (NYSE:ZYME)Raymond James Financial Inc. acquired a new position in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 60,642 shares of the company's stock, valued atApril 6, 2025 | marketbeat.comInsider Buying: Zymeworks Inc. (NYSE:ZYME) Director Acquires 4,397 Shares of StockZymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc purchased 4,397 shares of Zymeworks stock in a transaction dated Monday, March 31st. The shares were bought at an average price of $11.75 per share, for a total transaction of $51,664.75. Following the acquisition, the director now owns 17,259,548 shares in the company, valued at approximately $202,799,689. This trade represents a 0.03 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.April 4, 2025 | marketbeat.comInsider Buying: Zymeworks Inc. (NYSE:ZYME) Director Purchases 74,360 Shares of StockZymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc bought 74,360 shares of the firm's stock in a transaction that occurred on Wednesday, April 2nd. The stock was purchased at an average price of $11.85 per share, with a total value of $881,166.00. Following the completion of the purchase, the director now owns 17,382,566 shares in the company, valued at approximately $205,983,407.10. This trade represents a 0.43 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.April 4, 2025 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Director Purchases $51,664.75 in StockApril 3, 2025 | insidertrades.comZymeworks Inc. sees insider purchases totaling $1.5 millionApril 2, 2025 | investing.comEcor1 Capital, Llc Buys 43,848 Shares of Zymeworks Inc. (NYSE:ZYME) StockZymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc bought 43,848 shares of the business's stock in a transaction that occurred on Wednesday, March 26th. The shares were bought at an average cost of $12.24 per share, for a total transaction of $536,699.52. Following the transaction, the director now owns 17,255,151 shares of the company's stock, valued at $211,203,048.24. The trade was a 0.25 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.March 28, 2025 | marketbeat.comInsider Buying: Zymeworks Inc. (NYSE:ZYME) Director Purchases 43,848 Shares of StockMarch 28, 2025 | insidertrades.comZymeworks Inc.: Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual MeetingMarch 26, 2025 | finanznachrichten.deInsiders Make Huge Purchases of These 4 Biotech StocksMarch 26, 2025 | 247wallst.com Get Zymeworks News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter. Email Address ZYME Media Mentions By Week ZYME Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ZYME News Sentiment▼1.020.64▲Average Medical News Sentiment ZYME News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ZYME Articles This Week▼135▲ZYME Articles Average Week Get Zymeworks News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SWTX News ZLAB News VKTX News PTCT News CRNX News SRRK News MRUS News CPRX News XENE News MOR News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ZYME) was last updated on 5/7/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zymeworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
